[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL REGENERATIVE MEDICINE MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL REGENERATIVE MEDICINE MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 CELL THERAPY
5.3 GENE THERAPY
5.4 TISSUE ENGINEERING
5.5 SMALL MOLECULE & BIOLOGIC

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY MATERIAL
6.1 OVERVIEW
6.2 SYNTHETIC MATERIAL
6.2.1 SCAFFOLD
6.2.2 ARTIFICIAL VASCULAR GRAFT MATERIAL
6.2.3 HYDROGEL MATERIAL
6.3 BIOLOGICALLY DERIVED MATERIAL
6.3.1 COLLAGEN
6.3.2 XENOGENEIC MATERIAL
6.4 GENETICALLY ENGINEERED MATERIAL
6.4.1 GENETICALLY MANIPULATED CELL
6.4.2 THREE-DIMENSIONAL POLYMER TECHNOLOGY
6.4.3 TRANSGENICS
6.4.4 FIBROBLAST
6.4.5 NEURAL STEM CELL
6.4.6 GENE-ACTIVATED MATRICES
6.5 PHARMACEUTICAL
6.5.1 BIOLOGIC 

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 CARDIOVASCULAR
7.3 ONCOLOGY
7.4 DERMATOLOGY
7.5 MUSCULOSKELETAL
7.6 WOUND HEALING
7.7 OPHTHALMOLOGY
7.8 NEUROLOGY
7.9 OTHERS

8 GLOBAL REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY
8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO

8.3 EUROPE

8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE

8.4 ASIA PACIFIC

8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC

8.5 MIDDLE EAST & AFRICA

8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA

8.6 SOUTH AMERICA

8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA

9 GLOBAL REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES

10 COMPANY PROFILES

10.1 3M COMPANY
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS

10.2 ATHERSYS, INC.
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS

10.3 CRYOLIFE, INC.
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS

10.4 INTEGRA LIFESCIENCES CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS

10.5 ISTO BIOLOGICS (ISTO BIOLOGICS MEDICAL SYSTEMS, INC.)
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS

10.6 MEDTRONIC PLC
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS

10.7 ORGANOGENESIS INC.
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS

10.8 STRYKER CORPORATION
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS

10.9 U.S. STEM CELL, INC.
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS

10.10 ZIMMER BIOMET HOLDINGS, INC.
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS